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ABSTRACT
Objectives: To study the association between
exposures to glucose-lowering therapy and risk of
cancer using the nationwide administrative registers in
Denmark.
Design: Nationwide cohort study.
Setting: All hospitals in Denmark.
Participants: All individuals aged $35 years in
1998e2009 who were naive to glucose-lowering
treatment and had no history of cancer. Primary
measures outcomes: ﬁrst cancer diagnosis between
1998 and 2009. The RR of cancer as dependent on
exposure to individual glucose-lowering agents was
assessed by multivariable Poisson regression models.
Results: Of 159894 patients that initiated treatment
with glucose-lowering agents, 12789 developed
cancer, incidence rate 17.4/1000 person-years. Of the
remaining 3447904 individuals not using glucose-
lowering agents, 293878 developed cancer, incidence
rate 7.9/1000 person-years. Use of different types of
glucose-lowering agents including human insulin,
insulin analogues, as well as sulfonylureas were
associated with a quantitatively similar and
signiﬁcantly increased RR of cancer of 1.2e1.3
compared with unexposed individuals after
multivariable adjustment. For the majority of agents,
the authors identiﬁed the highest RR of cancer during
the ﬁrst 30 treatment days with a subsequent decline
of risk approaching the cancer risk of the background
population only 6e12 months after initiation of
treatments.
Conclusions: Use of most glucose-lowering agents
including sulfonylureas was associated with
a comparable increased risk of cancer shortly after
initiation of treatment and subsequently a decline to
the risk of the background population. This suggests
that the relation is not causal.
INTRODUCTION
Recent epidemiological studies have
reported a positive relationship between
cancer and use of insulin, which has caused
major safety concerns among patients as well
as clinicians.
1 Insulin is known to possess
afﬁnity for the insulin-like growth factor
(IGF)-1 receptor, which enhances cell growth
and increases resistance to apoptosis.
23
Receptor binding studies demonstrated that
different types of insulin analogues exhibit
different afﬁnities for the IGF-1 receptor
compared with native human insulin, and
studies have reported colorectal, breast and
prostate cell lines to proliferate in response
to exposure to some types of insulin analogues,
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ARTICLE SUMMARY
Article focus
- Several observational studies have suggested
that insulin therapy may increase the risk of
cancer. If insulin therapy causes/enhances
cancer development, the RR would be expected
to increase with longer treatment duration.
- The present study investigated the association
between treatment duration with individual
glucose-lowering agents and the RR of devel-
oping cancer in 3.6 million individuals.
Key messages
- Use of human insulin, insulin analogues and
sulfonylureas were associated with a signiﬁcantly
increased RR of cancer of 1.2e1.3 compared
with unexposed individuals.
- For all agents, the highest RR of cancer was
found during the ﬁrst 30 days of treatment.
Hereafter, the RR declined rapidly, reaching a RR
of cancer comparable to unexposed individuals
after only 6e12 months of therapy for most
agents.
- This strongly suggests that a previously reported
association between use of glucose-lowering
agents and increased risk of cancer is not
causal.
Strengths and limitations of this study
- This study was based on complete and nation-
wide administrative registers, thereby reducing
selection bias.
- Data on measurements on body mass index,
glucose regulation and family cancer history
were lacking.
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Open Access Researchbut not to human insulin.
4e6 To this end, some observa-
tional studies indicated that use of insulin glargine, being
the approved insulin analogue with the putative highest
afﬁnity for the IGF-1 receptor, is associated with a dispro-
portionately increased RR of cancer compared with
human insulin.
17 e9
Besides insulin, other features associated with diabetes
such as obesity and hyperglycaemia per se are known risk
factors of cancer with increased oxidative stress and DNA
damage representing suspected causal mechanisms.
10
Indeed, caution is warranted concluding from observa-
tional and non-randomised studies that treatment with
insulin or its analogues increases risk of cancer. Recent
data have demonstrated that the RR of cancer ﬂuctuates
over time, being highest at time of diagnosis when
treatment is initiated, supporting the notion of a poten-
tial observational bias.
11 While much attention has been
on the potential impact of insulin and insulin analogues
on the risk of cancer, little is known about the time
relationship between initiation of glucose-lowering
treatment and cancer diagnosis for individual glucose-
lowering agents including oral glucose-lowering agents.
We therefore examined the association between risk of
incident cancer and exposure to the most used indi-
vidual insulin agents (insulin glargine, insulin lispro,
insulin aspart, insulin detemir and human insulin), as
well as oral glucose-lowering agents (sulfonylureas (SU),
metformin and thiazolidinediones) using the entire
Danish population.
METHODS
Registers
The public ﬁnanced healthcare system provides
a unique possibility to hold complete and nationwide
registers on a variety of variables in Denmark. We used
four of these registers to obtain data for the present
study. The Central Population Register includes information
on all individuals living in Denmark. All individuals are
registered with date of birth and gender. The Danish
National Patient Register includes information on dates
and causes of hospitalisations in Denmark since 1978. All
hospitalisations are registered according to the Interna-
tional Classiﬁcation of Diseases (ICD) system. The Danish
National Prescription Register holds data on every
dispensed prescription in Denmark since 1995.
Dispensed drugs are registered by the Anatomical
Therapeutic Classiﬁcation (ATC) system with informa-
tion on date of dispensing and amount dispensed avail-
able. Because of partial reimbursement of drug
expenses, the accuracy of the register is very good.
12
In the National Causes of Deaths Register, all deaths occur-
ring in Denmark are registered within 2 weeks after
occurrence.
Study population
We identiﬁed all Danish individuals who had not
claimed a prescription for glucose-lowering agents in
1995e1997 and who had never had cancer, as deemed by
any cancer diagnoses in 1978e1997, and who were
$35 years old during follow-up. Exposure to the
following glucose-lowering agents was identiﬁed: insulin
glargine (Lantus ATC-code A10AE04), insulin lispro
(Humalog ATC-code A10AB04, Humalog Mix
A10AD04), human insulin (Actrapid ATC-code
A10AB01, Insulatard ATC-code A10AC01, Mixtard
ATC-code A10AD01), insulin aspart (NovoRapid ATC-
code A10AB05, NovoMix ATC-code A10AD05), insulin
detemir (Levemir; ATC-code A10AE05), metformin
(ATC-code A10BA02), SU (ATC-code A10BB01,
A10BB03, A10BB07, A10BB09, A10BB12) and thiazoli-
dinediones (ATC-code A10BG02, A10BG03, A10BX02).
Duration of treatment was calculated from dates of
claimed prescriptions and the dispensed quantity of
insulin agents (international units (IU)) and number
and strength of tablets for oral glucose-lowering agents,
respectively. Individual doses (and thus duration of
treatment) were calculated by consideration of up to
seven consecutive prescriptions and a continuous treat-
ment period was assumed if this was compatible with at
least the minimal daily dose (1 IU for insulin agents and
0.5 tablet of oral glucose-lowering agent), as done
previously.
13e15 For the present study, individuals were
classiﬁed as exposed between the ﬁrst claimed prescrip-
tion and until estimated duration of last claimed
prescription.
Comorbidity
Charlson comorbidity index was used for adjustment of
comorbidity in all analyses.
16 The index was calculated
after time had been split (see Methods section for
description) using the left end point as reference. All
diagnoses within 10 years prior to the left end point were
considered (diabetes and cancer-related diagnoses not
included).
Outcomes
The end point was any incident cancer reported in the
Danish National Hospitalisation Register between 1998
and 2009 (ICD-10 codes C01eC99). Individuals were
censored at time of ﬁrst cancer, death or at the end of
2009. To explore whether distribution of cancers
differed according to exposure to individual insulin
agents, the following selected groups of cancers
(according to ICD-10 codes) were identiﬁed: gastroin-
testinal cancers (C15eC25), lung cancer (C34), prostate
cancer (C61), breast cancer (C50), gynaecological
cancers (C51eC57) and urological cancers (C64eC67).
It should be noted that Denmark possesses a speciﬁc
national cancer register, in which additional information
on, for example, tumour stages is available. The cancer
register is mainly based on the national patient register,
but some of the diagnoses are manually reviewed in the
cancer register, resulting in a discard of a minor part of
the cancer diagnoses from the national patient register.
For the present analyses, the national patient register
was nevertheless considered sufﬁcient in order to inves-
tigate the aims of the present paper. We did compare our
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Use of glucose-lowering agents and cancer riskend points with the diagnoses in the cancer register (we
had data available for 1998e2006 from this latter
register) and found a concordance rate exceeding 90%.
Statistics
The RR of cancer as dependent on use and duration of
individual glucose-lowering pharmacotherapy was
examined with multivariable Poisson regression models.
The whole cohort was included on 1 January 1998 or at
their 35th birthday if younger than 35 years at 1 January
1998.
The lexis-macro (http://192.38.117.59/wbxc/Lexis/
Lexis.sas; last accessed 8 January 2012) was used for all
analyses and included two time scales: calendar time
(bands were split in 1-year periods after 1 January 1998)
and duration of glucose-lowering treatment (bands were
split at every change in glucose-lowering treatment
regimens as well at 1, 3, 6, 12 months and every year
hereafter). Dichotomous variables were hereafter
created for the use of glucose-lowering agents (current
use or no use; left end point as reference). Similarly,
dichotomous variables were created for use of glucose-
lowering agents in speciﬁc time intervals (eg, ‘use of
actrapid day 0e30’ yes vs no; left end point as reference).
Age and comorbidity scores were calculated at the
beginning of each interval. For adjustment for the
effects of age in Poisson analyses, age was round in 0.5-
year intervals.
Two different multivariable Poisson analyses (both
being adjusted for Charlson comorbidity score, gender,
age and calendar year) were performed. In the ﬁrst
analysis, RRs associated with current use of the different
glucose-lowering agents were explored. In the second
analysis, the importance of time since initiation of the
different agents was explored (variables were included as
use vs no use of a speciﬁc agent in a speciﬁc time window
(eg, ‘actrapid day 0e30’, ‘humalog day 365.25e730.5’
etc)).
Calculations were performed using SAS V.9.2 (SAS
institute).
RESULTS
Of totally 3607798 individuals included, 159894 initi-
ated treatment with glucose-lowering agents. Table 1
presents total numbers of individuals ever exposed and
the cumulative exposure time for individual glucose-
lowering agents. The most frequently used agents
included human insulin and oral glucose-lowering
agents. Insulin lispro had a low numbers of users and
contributed only with a low cumulative exposure time.
RR of cancer
Crude incidence rates, numbers and cancer types are
shown in table 1. The distributions of cancer types were
similar within the different exposure groups and in the
unexposed population group. In multivariable analysis,
male gender, increasing age (up to 85 years) and
increasing Charlson comorbidity scores were found to be
associated with an increased risk of cancer. Figure 1
presents the rate ratio (RR) of cancer associated with use
of individual glucose-lowering agents. Besides
metformin, most agents were associated with a signiﬁ-
cant increase in RR compared with the background
population. Pooling all insulin analogues into one group
and all human insulin agents into another group gave
similar results: RR of cancer for use of human insulin
was 1.40 (95% CI 1.33 to 1.48) and for use of insulin
analogues, it was 1.14 (1.05 to 1.23). As illustrated in
ﬁgure 2AeC, there was a signiﬁcant ﬂuctuation in RR of
cancer over time. The ﬁrst 30-day period after initiation
of glucose-lowering treatment was associated with a very
pronounced increase in RR of cancer for most agents,
which subsequently declined rapidly during the ﬁrst year
of treatment, resulting in a RR of 1 after approximately
a half to 1 year of treatment.
DISCUSSION
In the present nationwide study including more than 3.5
million unselected individuals aged $35 years who were
naive to glucose-lowering pharmacotherapy at study
baseline, we found that use of several different types of
glucose-lowering agents, including use of the oral
glucose-lowering agent group SU, were associated with
an increase in RR of all types of cancer of approximately
20%e30%. Importantly, this risk was found to be highly
ﬂuctuating over time with, for example, more than
a twofold increase in RR of cancer already during the
ﬁrst 30 days after treatment initiation with insulin.
Interestingly, the RR of being diagnosed with cancer
declined signiﬁcantly within the ﬁrst year after onset of
treatment down to that of the background population
for all the studied agents. Data from the present
nationwide study therefore suggest that the previously
reported associations between an increase in risk of
cancer and use of insulin are most likely to be driven by
confounding and/or surveillance bias.
From the present study, it was impossible to investigate
what may have caused the ﬁndings, but it is known that
hyperglycaemia and cancer are more commonly seen
together than expected by chance.
7 In our study popu-
lation, initiation and use of glucose-lowering therapy
may have mirrored poor glycaemic control, occult
cancer or both. Hyperglycaemia has previously been
shown to increase the risk of several cancer types.
17 18
Elevated stress levels, as seen in many cancer types, are
associated with increasingly fasting serum glucose
levels,
19 and patients with cancer are often insulin
resistant,
20 which may unmask overt diabetes in predis-
posed individuals. The immediate risk of cancer on start
of insulin therapy is therefore likely to be driven by
diagnostic investigation when one of the diagnoses was
made. A true risk of cancer caused by insulin therapy
would be expected to remain high or even increase over
time.
The present study lacked data on several important
variables such as body mass index, HbA1c concentrations,
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Use of glucose-lowering agents and cancer riskphysical activity, family cancer history, alcohol consump-
tion, dietary pattern and smoking habits, and it was not
designed or powered to answer questions about the risk
of different cancer subtypes or about the safety proﬁles
of individual insulin analogues. As for the risk of speciﬁc
cancers with glucose-lowering treatments, it must be
emphasised that the pattern of cancer subtypes was
similar within all treatment subgroups and the control
group who were not on any glucose-lowering therapy.
Thus, even though we cannot exclude having over-
looked associations between treatments and risk of any
cancer subtypes, it seems unlikely that any quantitative
major causal associations have been overlooked. Of
particular relevance, the previously raised concerns
about the risk associated with use of insulin glargine
could not be thoroughly investigated in the present
study because we had rather few individuals using this
agent and very few patients using glargine developed
cancers, as compared with previous studies.
1 89
Furthermore, patients were only considered at risk, while
using a speciﬁc agents meaning that cancers occurring
after treatment cessation with a speciﬁc agent may be
overlooked. Nevertheless, it is interesting to speculate
whether and the extent to which the time from initiation
of glucose-lowering treatment may have biased the
ﬁndings of previous studies. At least when considering
the time of the observation period, insulin glargine
wasdand to some extent still isda relatively new agent
on the market, and it is likely that patients with new-
onset diabetes were more prone to initiate treatment
with insulin glargine compared with patients being well
regulated on older agents. In this context, a Swedish
study did not exclude patients with prior use of insulin,
and during a short follow-up time of maximally 2 years,
they found that use of insulin glargine as monotherapy
was associated with a twofold increase in the risk of
breast cancer as compared with use of other types of
insulin.
9 Similar, a German study had a signiﬁcantly
longer follow-up time for patients on human insulin
than for patients on insulin glargine, which may have
contributed to their ﬁndings of an increased risk of
cancer associated with insulin glargine.
8 In a third
Scottish study investigating the risk of cancer as depen-
dent on insulin glargine, on the other hand, three
speciﬁc exposure groups were identiﬁed: insulin glar-
gine monotherapy, insulin glargine + non-glargine
insulin and non-glargine insulin monotherapy.
1
Compared with the other two groups, the insulin glar-
gine monotherapy group had signiﬁcantly shorter
treatment duration prior to study start. The study
demonstrated no excess increase in risk of cancer for the
use of insulin glargine, but when restricting the analysis
to patients on insulin glargine as monotherapy, these
patients were found to have a higher RR of all cancers as
Figure 1 RR of cancer according to exposure to individual
glucose-lowering agents.
Figure 2 RR of cancer according to exposure length of individual glucose-lowering agents: (A) human insulin; (B) insulin
analogues; (C) oral agents.
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Use of glucose-lowering agents and cancer riskwell as breast cancers compared with patients on non-
glargine insulin. The authors concluded that their
ﬁnding may be due to allocation bias rather than an
effect of insulin glargine itself, which our data support.
Altogether, more studies are needed to answer this
question, and in particular, our results demonstrate that
it is of crucial importance to take treatment duration
into account, in order to eliminate confounding-by-
indication/surveillance bias.
As also shown in at least one previous study,
21 another
interesting ﬁnding of this study was that use of SU was
associated with a risk of cancer quantitatively similar to
that of insulin in overall analysis. While it theoretically
could be speculated that the effect of SU’s to increase
insulin levels in plasma could represent a causal mech-
anism, the ﬁnding that this excess risk diminished with
duration of treatment, mirroring the relationship
between insulin and cancer, makes this highly unlikely to
be the case. Indeed, this ﬁnding is fully in agreement
with the idea that newly diagnosed diabetes patient are
more often to be diagnosed as having cancer, and vice
versa, all together supporting that the association
between glucose-lowering agents and cancer at least to
some signiﬁcant extent may represent confounding.
Finally, very recent data from the Food and Drug
Administration side effect registry reported increased
risk of some types of cancer in patients treated for rela-
tively short periods with the novel glucagon-like peptide
(GLP)-based therapies.
22 The current data raise the
possibility that confounding and lack of correction for
time of treatments to some unknown extent may explain
the risk of cancers associated with GLP-1-based thera-
pies.
CONCLUSIONS
Use of most glucose-lowering agents including insulin
was associated with an overall increased risk of cancer.
However, this increase was due to an association
observed early in treatment only, suggesting that the
association may not be causal. More studies are
warranted to further investigate this hypothesis.
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